

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Christopher Wheeler <i>et al.</i>	Examiner:	To be assigned
Serial No.:	10/575,438	Group Art Unit:	1642
Filed:	April 11, 2006	Docket:	67789-570
Title:	SYSTEM AND METHOD FOR THE TREATMENT OF CANCER, INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM		

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and that documents listed on the attached PTO/SB/08a Form be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request a copy of the PTO/SB/08a Form be initialed as being considered by the Examiner and returned to the Applicants with the next official communication.

No fee is due pursuant to 37 C.F.R. §1.97(b)(3). If additional fees are believed necessary, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 04-0258.

**Information Disclosure Statement**

Serial No.: 10/575,438

Filing Date: April 11, 2006

Title: SYSTEM AND METHOD FOR THE TREATMENT OF CANCER,  
INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM


**Page 2**

Docket No. 67789-570

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

April 30, 2007

Respectfully submitted,  
Christopher Wheeler *et al.*  
DAVIS WRIGHT TREMAINE LLP

By   
Linda B. Truong  
Registration No. 56,461

865 South Figueroa Street  
Suite 2400  
Phone: (213) 633-6800  
Facsimile: (213) 633-6899

<b>Application Number</b>	10/575,438
<b>Filing Date</b>	April 11, 2006
<b>First Named Inventor</b>	Christopher Wheeler
<b>Art Unit</b>	1642
<b>Examiner Name</b>	To be assigned
<b>Attorney Docket Number</b>	67789-570

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER initiates if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number optional. <sup>1</sup> See *Kinds Codes* of the USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>2</sup> Enter Office that issued the document, but the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the receipt of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b> 10/575,438	
(Use as many sheets as necessary)		<b>Filing Date</b> April 11, 2006	
		<b>First Named Inventor</b> Christopher Wheeler	
		<b>Art Unit</b> 1642	
		<b>Examiner Name</b> To be assigned	
<b>Sheet</b> 2	<b>of</b> 2	<b>Attorney Docket Number</b> 67789-570	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	9	SHIN et al., Antitumor Effect of Intratumoral Administration Of Dendritic Cell Combination With Vincristine Chemotherapy In A Murine Fibrosarcoma Model, Histology and Histopathology, April 2003, pp. 435-447, 18:2.	
	10	YU et al., Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer, Clinical Cancer Research, January 2003, pp. 285-294, 9:1.	
	11	TANAKA et al., Intratumoral Injection of Dendritic Cells After Treatment of Anticancer Drugs Induces Tumor-Specific Antitumor Effect In Vivo, International Journal of Cancer, September 20, 2002, pp. 285-289, 101:3.	
	12	GHOSH et al., Dendritic Cell-Based Immunotherapy Combined With Antimony-Based Chemotherapy Cures Established Murine Visceral Leishmaniasis, The Journal of Immunology, June 1, 2003, pp. 5625-5629, 170:11.	
	13	INOUE et al., Dendritic Cell Collected With Tumor Cells Treated With An Anticancer Drug To Induce Tumor Rejection, Surgery Today, April 4, 2003, pp. 269-276, 33:4.	
	14	REICHARDT et al., Idiotype Vaccination Of Multiple Myeloma Patients Using Monocyte-Derived Dendritic Cells, Haematologica, October 2003, pp. 1139-1149, 88:10.	
	15	CHUI et al., Dendritic Cell Vaccination Following High Dose Chemotherapy With Autologous Stem Cell Support For Breast Cancer: Long-Term Follow-Up, Proceedings of the American Society of Clinical Oncology, June 2003, 22 (ABSTRACT ONLY).	
	16	CASTRO et al., Current and Future Strategies For The Treatment Of Malignant Brain Tumors, Pharmacology & Therapeutics, April 2003, pp. 71-108, 98:1.	
	17	POLLACK et al., Exploitation of Immune Mechanisms in the Treatment of Central Nervous System Cancer, Seminars in Pediatric Neurology, June 2000, pp. 131-143, 7:2.	
	18	YU et al., Vaccination of Malignant Glioma Patients With Peptide-Pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-Cell Infiltration, Cancer Research, February 1, 2001, pp. 842-847, 61:3.	
	19	STEINMAN, R.M., Some Interfaces of Dendritic Cell Biology, Acta Pathologica, Microbiologica, et Immunologica Scandinavica, July 2003, pp. 675-697, 111:7-8.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.